GLP-1 Medicines After Weight-Loss Surgery in Chinese Adults With Obesity
Tests semaglutide, mazdutide or tirzepatide after weight-loss surgery in adults with obesity.
Plain-language title generated from the registry record
Registry title: GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07633639, who can take part
Where in China
- China-Japan Friendship HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT07633639
- Record updated
- 8 June 2026
- Original description
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.Read full original descriptionShow less
The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.
Inclusion: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG); obesity:BMI ≥30 kg/m²; Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria; Age range: 18-60 years (inclusive); Informed consent: Willing participation with documented consent.
Exclusion: Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively; Prior bariatric surgery: History of any metabolic/bariatric surgical procedure; Non-indicated candidates: Patients not meeting standard bariatric surgery indications; Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak); Significant comorbidities:; 5.1Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).